361 related articles for article (PubMed ID: 2991678)
21. [Binding sites of opiates and endogenous opioids in the oocytes of the toad Bufo viridis].
Bakalkin GIa; Iakovleva TV; Korobov KP; Bespalova ZhD; Vinogradov VA
Biokhimiia; 1984 Jun; 49(6):883-8. PubMed ID: 6087934
[TBL] [Abstract][Full Text] [Related]
22. Site-directed alkylation of multiple opioid receptors. I. Binding selectivity.
James IF; Goldstein A
Mol Pharmacol; 1984 May; 25(3):337-42. PubMed ID: 6328259
[TBL] [Abstract][Full Text] [Related]
23. Discrimination of three opiate receptor binding sites with the use of a computerized curve-fitting technique.
Pfeiffer A; Herz A
Mol Pharmacol; 1982 Mar; 21(2):266-71. PubMed ID: 6124875
[TBL] [Abstract][Full Text] [Related]
24. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
25. Thermodynamic analysis of rat brain opioid mu-receptor-ligand interaction.
Zeman P; Tóth G; Kvetnanský R
Gen Physiol Biophys; 1987 Jun; 6(3):237-48. PubMed ID: 3040520
[TBL] [Abstract][Full Text] [Related]
26. Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system.
Tao R; Auerbach SB
J Pharmacol Exp Ther; 2002 Nov; 303(2):549-56. PubMed ID: 12388635
[TBL] [Abstract][Full Text] [Related]
27. [Alpha interferon interaction with opiate receptors in the rat brain].
Panchenko LF; Aliab'eva TN; Malinovskaia VV; Balashov AM
Biull Eksp Biol Med; 1987 Jul; 104(7):87-9. PubMed ID: 3040148
[TBL] [Abstract][Full Text] [Related]
28. [3H]Ethylketocyclazocine binding to mouse brain membranes: evidence for a kappa opioid receptor type.
Garzón J; Sánchez-Blázquez P; Lee NM
J Pharmacol Exp Ther; 1984 Oct; 231(1):33-7. PubMed ID: 6092603
[TBL] [Abstract][Full Text] [Related]
29. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
Ward SJ; Takemori AE
J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
[TBL] [Abstract][Full Text] [Related]
30. Naltrexone-induced opiate receptor supersensitivity.
Zukin RS; Sugarman JR; Fitz-Syage ML; Gardner EL; Zukin SR; Gintzler AR
Brain Res; 1982 Aug; 245(2):285-92. PubMed ID: 6289965
[TBL] [Abstract][Full Text] [Related]
31. Affinity labeling of mu and kappa receptors with naloxone benzoylhydrazone.
Standifer KM; Murthy LR; Kinouchi K; Steele L; Pasternak GW
Mol Pharmacol; 1991 Mar; 39(3):290-8. PubMed ID: 1848652
[TBL] [Abstract][Full Text] [Related]
32. An examination of the opiate receptor subtypes labeled by [3H]cycloFOXY: an opiate antagonist suitable for positron emission tomography.
Rothman RB; McLean S
Biol Psychiatry; 1988 Mar; 23(5):435-58. PubMed ID: 2894229
[TBL] [Abstract][Full Text] [Related]
33. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation.
Tempel A; Gardner EL; Zukin RS
J Pharmacol Exp Ther; 1985 Feb; 232(2):439-44. PubMed ID: 2982011
[TBL] [Abstract][Full Text] [Related]
34. Opioid receptor binding characteristics of the non-equilibrium mu antagonist, beta-funaltrexamine (beta-FNA).
Ward SJ; Fries DS; Larson DL; Portoghese PS; Takemori AE
Eur J Pharmacol; 1985 Jan; 107(3):323-30. PubMed ID: 2984010
[TBL] [Abstract][Full Text] [Related]
35. Saturable binding of dihydromorphine and naloxone to rat brain tissue in vitro.
Lee CY; Akera T; Stolman S; Brody TM
J Pharmacol Exp Ther; 1975 Sep; 194(3):583-92. PubMed ID: 1159633
[TBL] [Abstract][Full Text] [Related]
36. Ex vivo determination of opiate antagonist binding at mu-opioid ([3H]-DAGO) receptors in hypothalamic micropunches from maturing female rats: comparison between SDZ 210-096 and nalmefene.
Landymore KM; Giles A; Wilkinson M
Neuropeptides; 1992 Mar; 21(3):175-82. PubMed ID: 1321363
[TBL] [Abstract][Full Text] [Related]
37. The pattern of [3H]cyclofoxy retention in rat brain after in vivo injection corresponds to the in vitro opiate receptor distribution.
Ostrowski NL; Burke TR; Rice KC; Pert A; Pert CB
Brain Res; 1987 Feb; 402(2):275-86. PubMed ID: 3030494
[TBL] [Abstract][Full Text] [Related]
38. In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor.
Leysen JE; Gommeren W
Arch Int Pharmacodyn Ther; 1982 Dec; 260(2):287-9. PubMed ID: 6131653
[No Abstract] [Full Text] [Related]
39. Preparation of brain membranes containing a single type of opioid receptor highly selective for dynorphin.
James IF; Chavkin C; Goldstein A
Proc Natl Acad Sci U S A; 1982 Dec; 79(23):7570-4. PubMed ID: 6130527
[TBL] [Abstract][Full Text] [Related]
40. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.
Kim S; Wagner HN; Villemagne VL; Kao PF; Dannals RF; Ravert HT; Joh T; Dixon RB; Civelek AC
J Nucl Med; 1997 Nov; 38(11):1726-31. PubMed ID: 9374341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
